Sera Prognostics, Inc. SERA
We take great care to ensure that the data presented and summarized in this overview for SERA PROGNOSTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SERA
View all-
Baker Bros. Advisors LP New York, NY5.43MShares$32.9 Million0.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.03MShares$18.4 Million0.33% of portfolio
-
Interwest Venture Management CO2.42MShares$14.6 Million21.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.65MShares$10 Million1.88% of portfolio
-
Black Rock Inc. New York, NY1.41MShares$8.54 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.2MShares$7.27 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY885KShares$5.36 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA592KShares$3.59 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA587KShares$3.56 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY521KShares$3.16 Million0.56% of portfolio
Latest Institutional Activity in SERA
Top Purchases
Top Sells
About SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Insider Transactions at SERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
4,078
-2.25%
|
$28,546
$7.32 P/Share
|
|
Nov 11
2024
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,075
-1.45%
|
$84,525
$7.32 P/Share
|
|
Nov 11
2024
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
95
-1.39%
|
$665
$7.32 P/Share
|
|
Nov 11
2024
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,179
-2.4%
|
$50,253
$7.32 P/Share
|
|
Nov 11
2024
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,727
-3.64%
|
$33,089
$7.32 P/Share
|
|
Nov 11
2024
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
4,727
-3.48%
|
$33,089
$7.32 P/Share
|
|
Nov 11
2024
|
Benjamin Jackson General Counsel |
SELL
Open market or private sale
|
Direct |
4,727
-3.37%
|
$33,089
$7.32 P/Share
|
|
Oct 07
2024
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
96
-1.39%
|
$672
$7.15 P/Share
|
|
Sep 10
2024
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,085
-2.93%
|
$175,595
$7.57 P/Share
|
|
Sep 10
2024
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,056
-1.66%
|
$35,392
$7.57 P/Share
|
|
Sep 06
2024
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
96
-1.37%
|
$672
$7.16 P/Share
|
|
Aug 07
2024
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,760
-2.18%
|
$47,320
$7.42 P/Share
|
|
Aug 07
2024
|
Benjamin Jackson General Counsel |
SELL
Open market or private sale
|
Direct |
5,022
-3.46%
|
$35,154
$7.42 P/Share
|
|
Aug 07
2024
|
Mansoor Raza Mirza |
SELL
Open market or private sale
|
Direct |
101
-1.42%
|
$707
$7.42 P/Share
|
|
Aug 07
2024
|
Zhenya Lindgardt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,327
-1.42%
|
$86,289
$7.42 P/Share
|
|
Aug 07
2024
|
Paul Kearney Chief Data Officer |
SELL
Open market or private sale
|
Direct |
4,333
-2.34%
|
$30,331
$7.42 P/Share
|
|
Aug 07
2024
|
Robert Gardner Harrison Chief Information Officer |
SELL
Open market or private sale
|
Direct |
5,022
-3.57%
|
$35,154
$7.42 P/Share
|
|
Aug 07
2024
|
John J. Boniface Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,022
-3.72%
|
$35,154
$7.42 P/Share
|
|
Jul 13
2024
|
Marcus Dean Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,117
+50.0%
|
-
|
|
Jun 10
2024
|
Austin Aerts Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,415
-1.71%
|
$43,320
$8.11 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 73.4K shares |
|---|---|
| Grant, award, or other acquisition | 97.8K shares |
| Other acquisition or disposition | 9.01K shares |
| Open market or private sale | 436K shares |
|---|---|
| Other acquisition or disposition | 931K shares |